1. Academic Validation
  2. Structure-Affinity Relationships and Structure-Kinetic Relationships of 1,2-Diarylimidazol-4-carboxamide Derivatives as Human Cannabinoid 1 Receptor Antagonists

Structure-Affinity Relationships and Structure-Kinetic Relationships of 1,2-Diarylimidazol-4-carboxamide Derivatives as Human Cannabinoid 1 Receptor Antagonists

  • J Med Chem. 2017 Dec 14;60(23):9545-9564. doi: 10.1021/acs.jmedchem.7b00861.
Lizi Xia 1 Henk de Vries 1 Eelke B Lenselink 1 Julien Louvel 1 Michael J Waring Leifeng Cheng Sara Pahlén 2 Maria J Petersson 2 Peter Schell Roine I Olsson Laura H Heitman 1 Robert J Sheppard 3 Adriaan P IJzerman 1
Affiliations

Affiliations

  • 1 Division of Medicinal Chemistry, LACDR, Leiden University , 2300RA Leiden, The Netherlands.
  • 2 Medicinal Chemistry, Cardiovascular and Metabolic Diseases, IMED Biotech Unit, AstraZeneca , Gothenburg SE-431 83, Sweden.
  • 3 Medicinal Chemistry, Oncology, IMED Biotech Unit, AstraZeneca , Cambridge SK10 2NA, United Kingdom.
Abstract

We report on the synthesis and biological evaluation of a series of 1,2-diarylimidazol-4-carboxamide derivatives developed as CB1 receptor antagonists. These were evaluated in a radioligand displacement binding assay, a [35S]GTPγS binding assay, and in a competition association assay that enables the relatively fast kinetic screening of multiple compounds. The compounds show high affinities and a diverse range of kinetic profiles at the CB1 receptor and their structure-kinetic relationships (SKRs) were established. Using the recently resolved hCB1 receptor crystal structures, we also performed a modeling study that sheds light on the crucial interactions for both the affinity and dissociation kinetics of this family of ligands. We provide evidence that, next to affinity, additional knowledge of binding kinetics is useful for selecting new hCB1 receptor antagonists in the early phases of drug discovery.

Figures